TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb
Xiancai Ma,Tao Yang,Yuewen Luo,Liyang Wu,Yawen Jiang,Zheng Song,Ting Pan,Bingfeng Liu,Guangyan Liu,Jun Liu,Fei Yu,Zhangping He,Wanying Zhang,Jinyu Yang,Liting Liang,Yuanjun Guan,Xu Zhang,Linghua Li,Weiping Cai,Xiaoping Tang,Song Gao,Kai Deng,Hui Zhang
DOI: https://doi.org/10.7554/eLife.42426
IF: 7.7
2019-10-04
eLife
Abstract:Comprehensively elucidating the molecular mechanisms of human immunodeficiency virus type 1 (HIV-1) latency is a priority to achieve a functional cure. As current 'shock' agents failed to efficiently reactivate the latent reservoir, it is important to discover new targets for developing more efficient latency-reversing agents (LRAs). Here we found that TRIM28 potently suppresses HIV-1 expression by utilizing both SUMO E3 ligase activity and epigenetic adaptor function. Through global site-specific SUMO-MS study and serial SUMOylation assays, we identified that P-TEFb catalytic subunit CDK9 is significantly SUMOylated by TRIM28 with SUMO4. The Lys44, Lys56 and Lys68 residues on CDK9 are SUMOylated by TRIM28, which inhibits CDK9 kinase activity or prevents P-TEFb assembly by directly blocking the interaction between CDK9 and Cyclin T1, subsequently inhibits viral transcription and contributes to HIV-1 latency. The manipulation of TRIM28 and its consequent SUMOylation pathway could be the target for developing LRAs.
biology